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1. Introduction 
1.1. Causes and consequences of preterm birth and strategies for tocolytic therapy 
Historically, the definition of prematurity was 2500 grams or less at birth. The current World 
Health Organization definition of prematurity is a baby born before 37 weeks of gestation, 
counting from the first day of the last menstrual period. Preterm birth occurs in 11% of live 
births globally and accounts for 35% of all newborn deaths. The rate is very high in Hungary 
too, it was 8.9 % of the total live births in 2010 (Fogarasi-Grenczer and Balázs, 2012). 
Preterm birth is a significant public health concern, as it is associated with high risk of infant 
mortality, various morbidities in both the neonatal period and later in life, and causes a 
significant societal economic burden (Ferguson et al., 2013). Medical conditions such as 
anatomical disorder of the uterus, placenta praevia, chronic hypertension, diabetes, infections, 
preterm birth in previous pregnancy and stress are associated with preterm birth. Maternal age 
(younger than 16 or older than 40), low socio-economic status, drug or alcohol abuse, low 
maternal weight, racial and ethnic factors also play significant roles (Behrman et al., 2007). 
There are also problems brought about by infertility treatment that often results in twins and 
triplets who are more likely born preterm. Nevertheless, in 50% of all cases the cause of 
preterm birth can not be identified. 
Preterm-born babies are at higher risk for intraventricular bleeding, respiratory distress 
syndrome, bronchopulmonal dysplasia and necrotizing enterocolitis. Longer-term 
consequences of preterm birth may include respiratory, gastrointestinal problems, weak 
immune system, cerebral palsy, mental retardation, visual and hearing impairments, behaviour 
and social-emotional concerns, learning difficulties, and poor health and growth.  
Uncertainty continues about the best strategies for managing preterm labor. Management of 
preterm delivery includes beta mimetics such as ritodrine and terbutaline; magnesium 
sulphate; prostaglandin inhibitors (for example, indomethacin and ketorolac); calcium channel 
blockers such as nifedipine; nitrates (for example, nitroglycerine); oxytocin receptor blockers 
(for example, atosiban). A recent pooled meta-analysis and decision analysis of trials on 
tocolytics showed that to delay delivery for 48 hours and seven days, prostaglandin inhibitors 
were the best tocolytics. Prostaglandin inhibitors and calcium channel blockers had the 
highest probability of delaying delivery and improving neonatal outcomes (Haas et al., 2012). 
Bacterial vaginosis during pregnancy has been associated with poor perinatal outcomes and, 
in particular, preterm birth. Antibiotic treatment can eradicate bacterial vaginosis in 
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pregnancy, though the overall risk of preterm birth was not significantly reduced 
(Brocklehurst et al., 2013).  
As its underlying causes and molecular pathways have not been fully elucidated, there is a 
need for investigations of endogenous factors that might control uterine activity, with the 
perspective of improving tocolytic therapy. 
1.2 Nociceptin/orphanin FQ and the nociceptin receptor (NOP): isolation, structure and 
the biological effects. 
The peptide nociceptin/orphanin FQ (N/OFQ) was isolated for the first time in 1995 by two 
distinct research groups from rat and porcine brain (Meunier et al., 1995; Reinscheid et al., 
1995). N/OFQ consists of seventeen amino acids. It was nominated nociceptin referring to the 
hyperalgesic effects that it evokes after supraspinal administration (Meunier et al., 1995).  
In parallel it was also called orphanin FQ, which name was given by Reinscheid et al. due to 
its high affinity of binding to the orphan opioid receptor (ORL1, hereafter referred to as NOP). 
They involved the first and last amino acids of the protein in its nomenclature: F and Q were 
used to sign the amino acids phenylalanine on the N-terminal (Phe, F) and glutamine (Gln, Q) 
located in the C-terminal position (Reinscheid et al., 1995). According to the novel 
terminology it is commonly used as nociceptin/orphanin FQ (N/OFQ). 
The nociceptin receptor (NOP) is similar in sequence to opioid receptors. Moreover, N/OFQ 
has a primary structure similar to that of opioid peptides. The synthetic heptadecapeptide 
potently inhibits forskolin-stimulated adenylate cyclase in CHO (ORL1+) cells in culture; this 
inhibitory activity being not affected by the addition of opioid ligands, nor did the peptide 
activate opioid receptors. When injected intracerebroventricularly into mice, orphanin FQ 
caused a decrease in locomotor activity but did not induce analgesia in the hot-plate test. In 
the rat in vivo, nociceptin diminishes acetylcholine release in the striatum, reduces dopamine 
release, and prevents the stimulatory effect of morphine on this transmitter in the nucleus 
accumbens and also elevates extracellular glutamate and -aminobutyric acid levels in 
mesencephalic dopaminergic areas. The effect of nociceptin on the mesencephalic 
dopaminergic system might explain its actions on motor behaviour (Schlickera et al., 2000). 
However, the peptide produced hyperalgesia in the tail-flick assay. Thus, orphanin FQ may 
act as a transmitter in the brain by modulating nociceptive and locomotor behaviour 
(Reinscheid et al., 1995). N/OFQ could modulate the outcome of some inflammatory 
diseases, such as sepsis and autoimmune pathologies by mechanisms not clearly elucidated 
yet. In fact, human body fluid revealed increased levels of N/OFQ under sepsis, arthritis, and 
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Parkinson's diagnose. The functional capacity of NOP receptor was demonstrated in vitro and 
in vivo studies by the ability of N/OFQ to induce chemotaxis of immune cells, to regulate the 
expression of cytokines and other inflammatory mediators, and to control cellular and 
humoral immunity (Gavioli et al., 2011). The ventromedial nucleus (VMN) of the 
hypothalamus contains a population of neurons that inhibit feeding when they are active. The 
neuropeptide N/OFQ acts within the VMN to stimulate food intake. N/OFQ, through its 
receptor, directly inhibits these VMN neurons, thus by inhibiting anorexigenic VMN neurons, 
N/OFQ thereby allows the stimulation of food intake (Chee et al., 2011). The peptide induces 
vasorelaxation of isolated rat arteries (Gumusel et al., 1997) and inhibits contractions in 
isolated guinea-pig bronchus (Rizzi et al., 1999), ileum (Zhan et al., 1997), mouse vas 
deferens (Calo et al., 1996; Zhang et al., 1997) and rat bladder (Giuliani et al., 1998). 
Furthermore, it potently contracts isolated rat (Taniguchi et al., 1998) and mouse (Osinski et 
al., 1999) colon. The changes of N/OFQ levels may play an important role in the 
pathophysiological changes in perinatal ischemia and hypoxia as well (Gu et al., 2003). 
N/OFQ is essentially an anxiolytic peptide that plays a role in adapting to stress. N/OFQ 
counteracts the rewarding properties of abused drugs. N/OFQ has well-recognized diuretic 
actions that could explain increased fluid intake. The endogenous nociceptin system has a 
physiological role in mediating or regulating behavioral responses to alcohol, and that 
activating NOP receptors suppresses ongoing alcohol consumption or reinstatement of 
responding for alcohol. Alcohol-preferring rats acutely stimulated alcohol drinking, but 
produced a reversible suppression of drinking when administered repeatedly over seven days 
(Murphy et al., 2010). Intrahippocampal administration of nociceptin was shown to produce a 
profound impairment of spatial learning, first in rats (Sandin et al., 1997; Redrobe et al., 
2000) and later in mice (Kuzmin et al., 2009). In all these tissues, the NOP receptor seems to 
be present in the peripheral endings of sensory, parasympathetic, and/or sympathetic nerves, 
where it exerts prejunctionnal modulation of mediator release. Moreover, under physiological 
conditions N/OFQ is present in the plasma of humans, in several pathological conditions such 
as female fibromyalgia syndrome (decreased level) (Anderberg et al., 1998), postpartum 
depression (increased level) (Gu et al., 2003), and it is a paracrine mediator of the FSH effects 
in the regulation of spermatogenesis (Eto et al., 2012). N/OFQ also regulates the LH surge 
and ovarian function (Sinchak et al., 2006).These results suggest that N/OFQ level changes 
may play a role in the function of the female and male reproductive tract.  
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1.3 PNOC gene and NOP receptor: structure and tissue distribution 
It has been investigated that the PNOC gene transcript undergoes alternative splicing. So far, 
five splice variants of NOP receptor mRNA has been isolated. Except one slice variant that 
encodes a functional receptor which has been isolated from human tissue (Peluso et al., 1998), 
none of the other variants encode a full-length receptor (Mogil et al., 2001), but rather non-
functional truncated receptors. Both N/OFQ and its receptor share a high degree of sequence 
similarity to the opioid peptides and their corresponding receptors, respectively. However, 
N/OFQ does not activate opioid receptors, nor do the opioid peptides elicit biological activity 
at the NOP receptor (Reinscheid et al., 1998). There are structural similarities between the 
amino acid sequences of N/OFQ and dynorphin A. 
The NOP receptor is widely expressed in the central nervous system, particularly in the 
forebrain (cortical areas, olfactory regions, limbic structures, thalamus), throughout the 
brainstem (central periaqueductal gray, substantia nigra, several sensory and motor nuclei), 
and in both the dorsal and ventral horns of the spinal cord. Regions almost devoid of NOP 
receptors are the caudate-putamen and the cerebellum. The anatomic distribution of the NOP 
receptor also reveals that pharmacological effects, other than those on which many studies 
have already focused, are worthwhile to explore. Aside from the nervous system, the immune 
system is one of the principal locations of the NOP receptor. The NOP receptor was identified 
in the peripheral nervous system and several isolated organs. RT-PCR results indicate that the 
mRNA of NOP receptor is expressed in rat intestine and vas deferens (Wang et al., 1994) as 
well as porcine gastrointestinal tract and kidney (Osinski et al., 1999). NOP transcripts were 
also detected in several guinea-pig ganglia (Fischer et al., 1998; Kummer et al., 1997). 
Finally, high affinity binding sites for N/OFQ were detected in the retina (Makman et al., 
1997) and the heart (Dumont et al., 1998) of the rat. In the periphery N/OFQ precursor 
mRNA was also detected in human spleen, peripheral blood leukocytes, in the rat ovary and 
fetal kidney (Mollereau et al., 1996; Nothacker et al., 1996).  
The PNOC gene is highly conserved in the three species (human, mouse and rat) and displays 
organizational features that are strikingly similar to those of the genes of preproenkephalin, 
preprodynorphin, and preproopiomelanocortin, the precursors to endogenous opioid peptides, 
suggesting the four genes belong to the same family-i.e., have a common evolutionary origin. 
PNOC is also weakly expressed in the ovary. The presence in ovary and hypothalamus 
suggests that the N/OFQ system may also play a role in endocrine regulation (Mollereau et 
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al., 1996). However, the possible presence and actions of N/OFQ on the smooth muscle of the 
female reproductive organs have not been discussed. 
1.4 Nocistatin: structure and effects  
Okuda-Ashitaka isolated for the first time the other biologically active neuropeptide derived 
from the same precursor as N/OFQ (Okuda-Ashitaka et al., 1998). The endogenous 
heptadecapeptide nocistatin (NST) was isolated from bovine brains and recently identified in 
mouse, rat, and human brain and in human cerebrospinal fluid. Although human, rat and 
mouse NST produced larger respective counterparts with 30, 35, and 41 amino acid residues, 
all peptides showed the antinociceptive activity. This activity was ascribed to the carboxyl-
terminal hexapeptide Glu-Gln-Lys-Gln-Leu-Gln, which is conserved beyond species. 
Intrathecal administration of N/OFQ induced pain responses including allodynia and 
hyperalgesia. Simultaneous administration of NST blocked the allodynia and hyperalgesia 
whereas anti-NST antibody decreased the threshold for the N/OFQ-induced allodynia. NST 
also attenuated the allodynia and hyperalgesia evoked by prostaglandin E2 (PGE2) and the 
inflammatory hyperalgesia induced by formalin or carrageenan/kaolin, and reversed the 
N/OFQ-induced inhibition of morphine analgesia at picogram doses (Minami et al., 1994a, 
1994b, Taiwo and Levine, 1988 and Okuda-Ashitaka et al., 1998). Furthermore, NST 
counteracted the impairment of learning and memory induced by N/OFQ or scopolamine 
(Hiramatsu and Inoue, 1999). NST suppresses appetite (Olszewski et al., 2000) and induces 
gastric mucosal protection (Zádori et al., 2008). It has been demonstrated that NST binds to a 
binding site that is distinct from the NOP receptor (Okuda-Ashitaka and Ito, 2000 and 
Johnson and Connor, 2007). Fantin et al. also showed that the putative receptor of NST is 
probably a G protein–coupled one. NST inhibits 5-hydroxytryptamine release via a Gi/o 
protein-mediated pathway (Johnson and Connor, 2007 and Fantin et al., 2007).  
It has been demonstrated that chronic constriction injury and diabetic pain elicit specific 
significant increases in the levels of PNOC, N/OFQ and NST (Liu et al., 2012). 
Given the myorelaxant actions of opioids, these endometrial neuropeptides may participate in 
the control of myometrial contractility.  
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2. Aims 
The main focus of our study was to investigate the myometrial effect of the endogenous 
neuropeptides N/OFQ and NST which are physiologically present in the humans and rats, and 
additionally have a role in the pain transmission during delivery. Therefore the following aims 
were set: 
1. The main aim of the study was to investigate the roles and mechanisms of N/OFQ and 
NST in the uterine contractility in term-pregnant rat (day 22 of pregnancy) and in human 
myometrium obtained from full-term pregnancy and from preterm birth. 
2. We set out to investigate the effect of N/OFQ and NST on the uterine contractility in an 
isolated organ bath system in vitro, by using term-pregnant rat uterine samples and 
myometrial samples obtained from caesarean sections of term-pregnant women, and from 
preterm delivery. Our further aim was to test the expression of N/OFQ and NST in the rat 
myometrium with radioimmunoassay and to detect the presence of their common 
precursor PNOC mRNA with real-time PCR technique.  
3. The following aim was to find out the signalling pathways of N/OFQ and NST in the 
uterus with the means of [
35S]GTPγS binding assay (for G protein activation), enzyme 
immunoassay (cAMP accumulation) and in vitro contractility studies. We set out to 
investigate the possible role of the Ca
2+
-dependent (outward rectifying) K
+
 channels 
(BKCa) and the release of the sensory neuropeptide CGRP in the mechanism of action of 
N/OFQ and NST, as well as the influence of a hypocalcemic environment in the uterus-
relaxant effect of NST in the presence of NX. 
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3. Materials and methods 
3.1. Animals 
The animals were treated in accordance with the European Communities Council Directives 
(86/609/ECC) and the Hungarian Act for the Protection of Animals in Research 
(XXVIII.tv.32.§). All experiments involving animal subjects were carried out with the 
approval of the Hungarian Ethical Committee for Animal Research (registration number: 
IV./01758-2/2008) and under the control of the ISO-9001:2008 Quality Management System. 
Sexually mature female Sprague-Dawley rats (body mass: 160-200 g, 50-60 days old) were 
mated in the early morning hours. Copulation was confirmed by the presence of a copulation 
plug or spermatozoa in the vagina. The day of copulation was considered to be the first day of 
pregnancy. The animals were housed in temperature (20-23 C), humidity (40-60%) and light 
(12 h of light, 12 h of dark)-regulated rooms, with water and food intake available ad libitum.  
3.2. Human specimens 
Biopsy specimens of human myometrial tissue were obtained at cesarean section (performed 
in the Department of Obstetrics and Gynecology, University of Szeged) in the third trimester 
of pregnancy in two groups: at full-term birth (37-41 weeks of gestation; n=10) and at preterm 
birth (33-36 weeks; n=9). At full-term, cesarean delivery was indicated by a previous 
cesarean delivery, breech presentation, a suspected cephalopelvic disproportion or myopia. 
The parity varied from 0 to 3, and the mean maternal age was 28.4 years (21-35 years). None 
of the women received a tocolytic agent, and there were no signs of labour. 
Preterm delivery occurred in mothers with twin pregnancies, or labour was indicated by an 
ongoing infection, leukocytosis, toxaemia, foetal distress or growth restriction. In the preterm 
group, the parity varied from 0 to 3, and the mean maternal age was 28.2 years (18-38 years). 
Three of the 9 patients received tocolytic therapy (magnesium sulphate) to arrest preterm 
uterine contractions, which proved to be ineffective. All the operations were performed under 
spinal anaesthesia. The Ethical Committee of Albert Szent-Györgyi Clinical Centre, 
University of Szeged, approved the clinical protocol for the use of human tissue; the pregnant 
women signed an informed consent form, uninfluenced (registration number: 114/2009). 
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3.3. Real-time RT-PCR (reverse transcription polymerase chain reaction) studies 
3.3.1. Rat study: On selected days of late pregnancy (days 18, 20 and 22), rats were killed by 
CO2 inhalation, the uteri were excised and trimmed of fat, the feto-placental units were 
removed and the endometrium was denuded. The tissue samples were frozen immediately in 
liquid nitrogen, and then stored at -70 °C until analysis. The frozen samples were ground with 
a Micro-Dismembrator S homogenizer (Sartorius, Germany), and the total RNA was isolated 
with the TRIsure Kit according to the manufacturer’s instructions. RNA purity was controlled 
via the optical density at 260/280 nm with a BioSpec Nano instrument (Shimadzu, Japan); all 
samples exhibited an absorbance ratio in the range 1.6-2.0. RNA quality and integrity were 
assessed by agarose gel electrophoresis. One microgram of each sample of total RNA was 
used for reverse transcription and amplification (TaqMan RNA-to-CT 1-Step Kit and the Sensi 
FAST Probe Hi-Rox One-Step Kit). The following primers were used: assay ID 
Rn01637101_m1 for PNOC, Rn 00667869_m1 for ß-actin and Rn 01775763_g1 for GAPDH 
as endogenous controls. RT-PCR was performed by using the ABI StepOne Real-Time 
cycler. The fluorescence intensities of the probes were plotted against PCR cycle numbers. 
The amplification cycle displaying the first significant fluorescence signal increase was 
defined as the threshold cycle (CT). 
There is an ongoing debate about the applicability of beta-actin as a gene reference in the 
pregnant rat uterus, with no reassuring conclusion as yet (Kelly et al., 2003). Thus we have 
repeated our PCR studies also with GAPDH as a gene reference. We did not find differences 
in the change of PNOC mRNA when GAPDH was used as compared with beta-actin. 
3.3.2. Human tissue collection: The human uterus tissue samples were frozen in liquid 
nitrogen, and then stored at -70 °C until analysis. The frozen samples were ground with a 
Micro-Dismembrator S homogenizer (Sartorius, Germany), and the total RNA was isolated 
with the TRIsure Kit according to the manufacturer’s instructions. RNA purity was controlled 
via the optical density at 260/280 nm with a BioSpec Nano instrument (Shimadzu, Japan); all 
samples exhibited an absorbance ratio in the range 1.6-2.0. RNA quality and integrity were 
assessed by agarose gel electrophoresis. One microgram of each sample of total RNA was 
used for reverse transcription and amplification (TaqMan RNA-to-CT 1-Step Kit and the Sensi 
FAST Probe Hi-Rox One-Step Kit).  
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The following primers were used: assay ID Hs00173823_m1 for PNOC and Hs 01060665_g1 
for ß-actin as endogenous control. RT-PCR was performed by using the ABI StepOne Real-
Time cycler. The fluorescence intensities of the probes were plotted against PCR cycle 
numbers. The amplification cycle displaying the first significant fluorescence signal increase 
was defined as the threshold cycle (CT). 
3.4.  Radioimmunoassay (RIA) for N/OFQ and NST in the rat uterus  
The uterine levels of N/OFQ were measured in nonpregnant and 22-day pregnant rats and the 
levels of NST were evaluated in nonpregnant and 15-, 18-, 20- and 22-day pregnant rats. The 
extraction of N/OFQ and NST was carried out by a validated method (Tekes et al., 2005; 
Eun-Mee et al., 1999 and Hofbauer et al., 2000). Uteri were treated with 1.0 ml of 1 M acetic 
acid at 95 °C for 5 min, then cooled in ice-cold water bath for 10 min, then homogenized by 
an Ultra Turrax T25 Janke&Kunkel homogenizer at 20,000 rpm/min for 10 sec (IKA 
Labortechnik, Staufen, Germany), followed by sonication (Labsonic 2000, B. Braun AG, 
Melsungen, Germany) for 30 sec. Homogenates were repeatedly placed for 5 min in a 95 °C 
shaking water bath, then left to sediment for 10 min at 0 °C, and centrifuged in an Eppendorf 
centrifuge (A. Hettich, Tuttlingen, Germany) at 14,000 g for 10 min at 4 °C. 1.0 ml aliquots 
of the supernatants were mixed with an equal volume of 1% v/v trifluoroacetic acid (TFA I), 
loaded onto C18 Sep-Pack cartridges (ABL&E Jasco Hungary Ltd., Budapest), washed twice 
with TFA I, and then eluted with 60% acetonitrile in 0.1% TFA. Samples were freeze-dried 
by centrifugation (Savant Instruments Inc., Farmingdale, NY, USA). 
During the validation of the extraction procedure, the stability of N/OFQ as well as the 
reproducibility, recovery, and linearity of recovery in the concentration range of 1–100 
pg/100 mg tissue were determined. The recovery was 87% ± 0.68% (mean ± SEM), and all 
other parameters were in the normal ranges. During the validation of the extraction procedure 
stability of NST, reproducibility, recovery and linearity of recovery in the 10–500 pg/100 mg 
tissue concentration range were determined. Recovery was 89  0.87 %, and all the other 
parameters were in the normal range. 
The tissue extracts were subjected to radioimmunoassay (RIA) for N/OFQ using a 
commercially available 
125
I-N/OFQ RIA Kit (Nociceptin/Orphanin FQ [rat] - RIA Kit; 
Phoenix Pharmaceuticals Inc.) with a minimum sensitivity of 1 pg/ml and for NST using a 
commercially available 
125
I-Nocistatin RIA kit with minimum sensitivity of 10 pg/ml. Data 
were evaluated with Isodata 20/20 software (Isodata, Pittsburg, KS, USA) and by RIA-Mat 
280 (Byk-Sangtec, Dietzenbach, Germany). Significance was calculated by Student t-test. 
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3.5. Radioligand-binding experiments 
3.5.1. Membrane preparation 
Radioligand-binding experiments were carried out on nonpregnant or 22-day-pregnant
 
rat 
uterus membrane preparations. The uterine tissues were cut
 
and homogenized in ice-cold 
buffer (0.05 M Tris-HCl,
 
pH 7.4) using a Braun teflon-glass homogenizer (10-15 strokes), and 
filtered through four layers of gauze to remove large aggregates. The homogenate was 
centrifuged (Sorvall RC5C centrifuge, SS34 rotor) at 40,000 g for 20 min at 4 °C, and the 
resulting pellet was resuspended in fresh buffer and incubated for 30 min at 37 °C. The 
centrifugation step was repeated, and the final pellet was resuspended in 0.05 M Tris-HCl 
buffer (pH 7.4) containing 0.32 M sucrose and stored at
 –70 °C until use (Ligeti et al., 2005). 
Protein concentration was determined by the method of Bradford (Bradford et al., 1976). 
3.5.2. Radioligand-binding assay 
For the homologue displacement experiments, the reaction mixture contained 100 µl of 
membrane preparation
 
(~ 0.3-0.4 mg protein/ml), 100 µl of [3H]N/OFQ-NH2 with
 
a specific 
activity of 25 Ci/mM, and 100 µl of unlabelled N/OFQ (10-12–10-5 M) or 100 µl of incubation 
buffer (consisting of 0.05 M Tris-HCl, 0.01 M MgCl2 and
 
2.5% ethanol, pH 7.42) for total 
binding. Incubation was started
 
by addition of the membrane suspension, and continued in a 
shaking
 water bath until a steady state was achieved (24 °C, 60 min). At the end of the 
incubation, the bound radioligand was
 
separated from the residual free radioligand by rapid 
filtration
 
on a Brandel M24R Cell harvester (Semat, UK) through Whatman GF/C
 
filters 
(Semat Technical Ltd, St. Albans UK) pre-soaked in polyethyleneimine (0.3%, pH 10) for 30 
min and washed with
 
3 x 10 ml of ice-cold buffer (0.05 M Tris-HCl, pH 7.42). The 
radioactivity of the dried filters was detected in UltimaGold
TM
 F scintillation cocktail 
(Packard) with a Packard Tricarb 2300TR liquid scintillation counter (Ligeti et al., 2005).  
Specific binding was determined
 
by subtracting the non-specific binding value from the total 
binding
 
value. All assays were carried out at least 3 times in duplicate
 
and values are given as 
the mean ± S.E.M. The experiments were individually analyzed and the maximum numbers of 
binding sites (Bmax) and the equilibrium dissociation constants (Kd) were calculated.
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3.5.3. [
35
S]GTPS-binding assay 
The uterine tissue samples obtained from 22-day-pregnant rats were homogenized (Gündüz et 
al., 2006) and diluted in 50 mM Tris-HCl buffer (pH 7.4) to obtain appropriate protein 
content for the assays (~ 10 µg of protein/sample). The membrane fractions were incubated at 
30 °C for 60 min in Tris-EGTA buffer (pH 7.4) composed of 50 mM Tris-HCl, 1 mM EGTA, 
3 mM MgCl2, 100 mM NaCl, and containing 20 MBq/0.05 ml of [
35S]GTPγS (0.05 nM) and 
increasing concentrations of N/OFQ tested in the presence of excess GDP (30 µM) in a final 
volume of 1 ml, according to Sim et al. and Traynor and Nahorski (Sim et al., 1995; Traynor 
and Nahorski, 1995), with slight modifications. The effect of N/OFQ was investigated 
together with 10
-6 
M NX. The Gi-protein-activating effect of N/OFQ and NX was also 
measured in the presence of 500 ng pertussis toxin (PTX)/ml. Total binding (T) was measured 
in the absence of test compound; non-specific binding (NS) was determined in the presence of 
10 µM unlabelled GTPγS and subtracted from T. The difference (TNS) indicates the basal 
activity. Bound and free [
35S]GTPγS were separated by vacuum filtration through Whatman 
GF/B filters (Whatman, Dassel, Germany) with a Brandel M24R Cell harvester. Filters were 
washed three times with 5 ml of ice-cold buffer (pH 7.4), and the radioactivity of the dried 
filters was detected in UltimaGold
TM
 F scintillation cocktail (Packard) with a Packard Tricarb 
2300TR liquid scintillation counter. Stimulation is given as a percentage of the specific 
[
35S]GTPγS-binding observed in the absence of receptor ligands (basal activity). The 
[
35S]GTPγS-binding experiments were performed in triplicate and repeated at least three 
times. Data were analysed with the sigmoid dose–response curve fit option.  
3.6.  Measurement of uterine cAMP accumulation 
As cAMP elevation plays a major role in the relaxation of uterine smooth muscle, we set out 
to investigate its possible involvement in the N/OFQ and NST signalling. Uterine tissue 
samples were incubated in de Jongh solution at 37 °C, perfused with carbogen. cAMP 
accumulation was determined in the presence of the non-specific phosphodiesterase inhibitor 
3-isobutyl-1-methylxanthine (IBMX; 10
-3
 M; 10 min), OFQ alone (10
-8
 M; 10 min) or in 
combination with NX, NST alone (10
-8
 M; 10 min) or in combination with N/OFQ or NX, 
and the adenylyl cyclase activator forskolin (10
-5
 M; 10 min). The effect of the Gi/Go protein 
inhibitor PTX (500 ng/ml) on uterine cAMP accumulation was also tested in the presence of 
IBMX, N/OFQ, NX and forskolin. The samples were then immediately frozen in liquid 
nitrogen and stored until the extraction of cAMP. Frozen tissue samples were ground, 
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weighed, homogenized in 10 volumes of ice-cold 5% trichloroacetic acid and centrifuged at 
1000 g for 10 min. The supernatants were extracted with 3 volumes of water-saturated diethyl 
ether. After drying, the extracts were stored at -70 °C until the cAMP assay. Uterine cAMP 
accumulation was measured with a commercial competitive cAMP enzyme immunoassay 
(EIA) kit and tissue cAMP levels were expressed in pmol/mg tissue. All samples (n=4 in each 
group) were measured in duplicate in the EIA.  
3.7 In vitro contractility studies 
3.7.1. Rat uterus preparation 
On day 22 of pregnancy (at term), the rats were killed by CO2 inhalation, and the uteri were 
removed and prepared for the in vitro contractility assay (Klukovits et al., 2010). Briefly, the 
isolated uterine horns were placed immediately in an organ bath (de Jongh solution; 
containing in mM: 137 NaCl, 3 KCl, 1 CaCl2, 1 MgCl2, 12 NaHCO3, 4 Na2HPO4, 6 glucose; 
pH 7.4) perfused with a mixture of 95% oxygen and 5% carbon dioxide (carbogen) and 
trimmed of fat, and the foeto-placental units were removed. The temperature was maintained 
at 37 C. Four rings 0.5 cm long were sliced from the middle part of each horn, including 
implantation sites, and tested in parallel; they were mounted vertically in the above-
mentioned organ bath containing 10 ml of de Jongh solution. After mounting, the initial 
tension was set at 1.5 g and the rings were equilibrated for 60 min, with a solution change 
every 15 min.  
3.7.2. Nociceptin studies in rat uterine tissues 
In the isolated uterine rings, rhythmic contractions were elicited with 25 mM KCl.  
The effects of N/OFQ and/or NX on the uterine rings were measured in the concentration 
range of 10
-12
 – 10-7 M in a non-cumulative manner. After each concentration of N/OFQ or 
NX, the rings were washed 3 times, allowed to recover for 5 min, and then contracted again 
with KCl.  
In another set of experiments, uterine contractions were elicited with 10
-8
 M oxytocin and the 
contraction-inhibiting effects of N/OFQ alone and in combination with NX were tested in a 
non-cumulative manner. These experiments were carried out in the presence of the non-
selective K
+
 channel blocker tetraethylammonium (TEA; 10
-3
 M) and the BKCa-channel 
selective blocker paxilline (PAX; 5x10
-6
 M). 
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3.7.3. Nocistatin studies in rat uterine tissues 
In the isolated uterine rings, rhythmic contractions were elicited with 25 mM KCl or with 10 
nM oxytocin or with 1 μM PGF2α. Without washing out the contractile agents, the effects of 
NST on the uterine contractions were tested in the concentration range 10
-12
 – 10-6 M, in a 
noncumulative manner (as regards its peptide characteristic). After each concentration of 
NST, the rings were washed 3 times, allowed to recover for 5 min, and then contracted again 
with the above-mentioned agents. Following the oxytocin- and PGF2α-induced contractions, 
the contraction-inhibitory effect of NST was also investigated in the presence of N/OFQ (10
-8
 
M).  
Following the KCl-induced contractions, the contraction-inhibitory effect of NST was 
investigated in the presence of N/OFQ (10
-8
 M) and/or NX (10
-8
 M). The most potent 
inhibitory effect of NST was found in the KCl-induced contractions; this agent was therefore 
used to investigate the possible mechanism of NST in further studies. As NX induces an 
increase in inward Ca
2+
 currents (Kai et al., 2002), we conducted a series of experiments in a 
hypocalcemic environment in order to investigate whether the inhibitory effect of NX on the 
NST-induced uterus relaxation is mediated by the opening of inward rectifying Ca
2+
 channels. 
Thus the joint effect of NST and NX was studied in a modified de Jongh buffer, containing 
half the Ca
2+
 concentration (0.5 mM CaCl2) of the standard de Jongh buffer (Hajagos-Tóth et 
al., 2009). In order to investigate the participation of the outward rectifying K
+
 channels in 
mediating the effects of NST, tests were performed in the presence of the BKCa channel-
selective blocker PAX (5x10
-6
 M), against spontaneous uterine contractions. 
The possible involvement of the sensory neuropeptide CGRP in the actions of NST was also 
tested on uterine tissue. In this set of experiments, capsaicin (1 μM dissolved in physiological 
saline containing 6% Tween 80 and 8% ethanol; for 10 min) was used to deplete CGRP from 
the uterine sensory nerve endings (Holzer et al., 1991). After thorough washing out, the 
tissues were incubated with CGRP (0.1 μM; 20 min) (Sams-Nielsen et al., 2001) and washed 
again, and the effects of NST were tested as above. These experiments were performed in a de 
Jongh solution supplemented with protease inhibitors such as phenylmethanesulfonyl fluoride 
(1 μM), captopril (0.1 mM), dithiothreitol (0.5 mM), soy bean trypsin inhibitor (1 mM) and 
aprotinin (36,000 KIU/L).  
The tension of the myometrial rings was measured with a strain gauge transducer (SG-
02, Experimetria Ltd, Budapest, Hungary), and recorded and analyzed with the SPEL 
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Advanced ISOSYS Data Acquisition System (Experimetria Ltd, Budapest, Hungary). The 
areas under the curves of 4-min periods were evaluated; the effects of NST, N/OFQ and NX 
were expressed as percentages of KCl/oxytocin/PGF2α-induced or spontaneous contractions. 
The concentration-response curves were fitted and the geometrical mean of logEC50 values 
and maximum contraction-inhibitory values were calculated with the Prism 4.0 computer 
program (GraphPad Inc., San Diego, CA, USA). 
3.7.4. Human uterus preparation 
Each tissue sample (~10 × 10 × 30 mm) was obtained from the upper edge of a lower-
segment transverse incision, after delivery of the child, but before oxytocin was given to the 
mother. Tissues were stored in Krebs–Henseleit solution (containing in mM: 118 NaCl, 5 
KCl, 2 CaCl2, 0.5 MgSO4, 25 NaHCO3, 1 KHPO4, 10 glucose; pH 7.4) at 4 °C, until 
investigation, but within 12 hours of collection. 
Longitudinal myometrial strips (~3 × 5 × 10 mm) were mounted vertically in an organ bath 
containing 10 ml Krebs–Henseleit solution. The organ bath was maintained at 37 °C, and 
carbogen (95% O2 + 5% CO2) was bubbled through it. After mounting, the initial tension was 
set at 3.0 g and the rings were equilibrated for 90 min, with a solution change every 15 min. 
3.7.5. In vitro studies in human uterine tissues from full-term births and from preterm births 
In the isolated uterine rings, rhythmic contractions were elicited with 10
-8
 M oxytocin. The 
effects of N/OFQ and NST on the uterine contractions were tested in the concentration range 
10
-12
 – 10-6 M, in a non-cumulative manner. After each concentration of N/OFQ and NST, the 
rings were washed 3 times, allowed to recover for 5 min, and then contracted again with 
oxytocin. The uterus-relaxant effect of NST was also investigated in the presence of N/OFQ. 
Additionally, the uterus-relaxant effect of N/OFQ was investigated in the presence of NST.  
The tension of the myometrial rings was measured with a strain gauge transducer (SG-02, 
Experimetria Ltd, Budapest, Hungary), and recorded and analyzed with the SPEL Advanced 
ISOSYS Data Acquisition System (Experimetria Ltd, Budapest, Hungary). The areas under 
the curves of 6-min periods were evaluated; the effects of NST and N/OFQ were expressed as 
percentages of the oxytocin-induced contractions. 
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3.8 Chemicals 
The radioligand ([
3
H]N/OFQ) was radiolabelled by Drs Judit Farkas and Geza Toth 
(Biological Research Centre of the Hungarian Academy of Sciences, Szeged, Hungary). The 
125
I-Nociceptin Radioimmunoassay Kit was obtained from Phoenix Pharmaceuticals Inc., 
Belmont, CA, USA. Guanosine-5’-[-35S]-triphosphate ([35S]GTPS) was purchased from 
Amersham, UK. PTX was from Tocris Cookson Ltd., Avonmouth, UK. N/OFQ and NST 
were purchased from PolyPeptide Laboratories France SAS, Strasbourg, France. PGF2α, NX, 
forskolin, IBMX, cAMP Enzyme Immunoassay Kit, TEA, PAX, guanosine 5’-diphosphate 
(GDP), guanosine-5’-o-(3-thiotriphosphate) (GTPS), polyethyleneimine, capsaicin, soy bean 
trypsin inhibitor, dithiothreitol, phenylmethanesulfonyl fluoride and captopril were from 
Sigma-Aldrich Ltd, Budapest, Hungary. The TRIsure Kit and the Sensi FAST Probe Hi-Rox 
One-Step Kit was from Bioline Ltd. Budapest, Hungary. TaqMan RNA-to-CT 1-Step Kit, ß-
actin and GAPDH primers were obtained from Life Technologies, Budapest, Hungary. The 
125
I-Nocistatin RIA kit was from Phoenix Pharmaceuticals, Inc., purchased by Izinta Ltd., 
Budapest, Hungary. Aprotinin (Gordox
®
) and oxytocin were purchased from Richter-Gedeon 
Ltd. Budapest, Hungary. 
3.9 Statistical analyses 
Statistical analyses were carried out by ANOVA Newman-Keuls multiple comparison test 
with the Prism 4.0 computer program (GraphPad Inc., San Diego, CA, USA). This test makes 
pairwise comparisons of group means. The alpha level of Newman -Keuls test is 0.05. 
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4. Results 
4.1.  Investigations on 22-day pregnant rat uterus 
4.1.1. N/OFQ and NST tissue levels  
The tissue levels of N/OFQ were measured by RIA in the uteri of non-pregnant and 22-
day pregnant rats (n=5 for each group), and the myometrial NST levels were measured in the 
uteri of non-pregnant and 15, 18, 20, and 22-day pregnant rats respectively (n=6 for each 
group). In the 22-day pregnant rats, uterine N/OFQ concentration was significantly higher 
(P<0.05) than in the non-pregnant rats. The myometrial NST levels increased significantly as 
term was approached. The RIA experiments revealed that the levels of NST were relatively 
low on pregnancy days 15, 18 and 20 (P>0.05), then elevated significantly by day 22, the day 
of delivery; P<0.05 as compared with day 20. The NST levels on day 22 did not differ from 
the non-pregnant samples (Table 1).  
Tissue N/OFQ 
pg/100 mg uterine tissue ± S.E.M 
NST 
pg/100 mg uterine tissue ± S.E.M 
Non-pregnant 2.11 ± 0.21  47.07 ± 4.66  
15 day pregnant   17.49 ± 4.41 * 
18 day pregnant   17.15 ± 3.03 ns 
20 day pregnant   13.95 ± 1.82 ns 
22 day pregnant 3.65 ± 0.12  * 42.11 ± 6.27 * 
Table 1. Tissue N/OFQ and NST levels in non-pregnant, 15, 18, 20 and 22 day pregnant rats. 
*P<0.05, ns: nonsignificant. Significances are expressed relative to the value of the previous tested 
day. 
4.1.2. Radioligand-binding studies 
The presence of NOP receptors in the uterus was detected by radioligand-binding 
experiments (n=4 for each group). In the uteri of nonpregnant females, the maximum binding 
capacity (Bmax) of the NOP receptors was 87.3  5.2 fmol protein/mg membrane, with a 
dissociation constant (Kd) of 2.19  0.14  10
-8
 M. In the membrane fractions of the 22-day-
pregnant uteri, the corresponding Bmax and Kd values were 99.6  2.31 fmol protein/mg 
membrane and 1.95  0.09  10-8 M, respectively. No significant difference (P>0.05) was 
found between the Bmax or Kd values in the nonpregnant versus the 22-day pregnant rat uteri. 
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4.1.3. [
35
S]GTPS-binding assay 
Because the central effects of N/OFQ are mediated via the activation of Gi proteins 
coupled to the NOP receptors and also the outward rectifying K
+
 channels, the N/OFQ-
stimulated G protein activation was additionally tested on the membrane fractions of the 22-
day-pregnant rat uteri (Fig. 1). N/OFQ stimulated the [
35S]GTPγS binding through the NOP 
receptors by 119.1% ± 1.2%. In the presence of NX, the N/OFQ-stimulated G protein 
activation was decreased to 106.8% ± 1.2%. In the presence of PTX and NX, however, the 
maximum G protein activation decreased to 82.3% ± 3.0% with the activation declining to 
below the basal level (n=6 for each set of experiments; Table 2).  
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Fig. 1. Effect of nociceptin (N/OFQ) on G protein activation in the pregnant rat myometrium in vitro. 
N/OFQ increased the concentration of activated G protein in a dose-dependent manner (▲). The presence of 10-6 
M naloxone (NX) significantly decreased the nociceptin-induced G protein activation (■), while the Gi protein 
inhibitor pertussis toxin (PTX) elicited a strong decline in activated G protein level (●). n=6; *P<0.05, **P<0.01, 
***P<0.001.  
 logEC50 (± S.E.M.) Emax (% ± S.E.M.) 
N/OFQ -8.59 ± 0.17 119.1 ± 1.19 
N/OFQ+NX -8.35 ± 0.50 106.8 ± 1.26 *** 
N/OFQ+NX+PTX -6.71 ± 0.29 82.35 ± 3.04 *** 
Table 2. logEC50 and maximum inhibitory values of nociceptin (N/OFQ) alone and in the presence of naloxone 
(NX) and of NX with pertussis toxin (PTX) on G protein activation in 22-day-pregnant uterine rings from the rat 
(n=6); ***P<0.001; significances are expressed relative to N/OFQ. 
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4.1.4. In vitro contractility studies 
4.1.4.1. Investigation of the contraction-inhibiting effects of N/OFQ, NST, and NX 
The KCl-evoked rhythmic contractions in the pregnant rat uterus were inhibited in a 
concentration-dependent manner by N/OFQ. In the presence of the opioid antagonist NX, the 
maximum contraction-inhibiting effect of N/OFQ was increased (Figure 2A, Table 3). NX 
alone caused a non-significant inhibition of the KCl-evoked contractions (n=8 for each set of 
experiments; data not shown). 
The contraction-inhibitory effect of NST was investigated in three different agonist-
induced contractions. The oxytocin-, PGF2α- or KCl-stimulated contractions did not decrease 
significantly through the experiment. Oxytocin was able to contract the uterine smooth 
muscle, but in the presence of oxytocin, NST alone or in the presence of N/OFQ (10
-8
 M), did 
not significantly reduce the contractions (data not shown). In the case of PGF2α-induced 
contractions, NST and N/OFQ displayed slight inhibitory effects (Fig. 2B). There was no 
significant difference between the logEC50 values. NST alone decreased the KCl-induced 
contractions concentration-dependently. Co-administration of N/OFQ (10
-8
 M) with NST, 
however, significantly increased the maximum contraction-inhibitory effect of NST; P<0.05 
(Fig. 2C). There was no significant difference between the logEC50 values (Table 4).  
The maximum inhibitory effect of NST was decreased by NX (10
-8
 M); P<0.001. There was 
no significant difference between the logEC50 values (Table 6). NX also decreased the 
maximum contraction-inhibitory effect of the combination NST+N/OFQ; P<0.05 (Fig. 2C). 
There was no significant difference between the logEC50 values (Table 4). 
  23 
 
A. 
-12 -11 -10 -9 -8 -7
0
10
20
30
40
50
60
70
N/OFQ
N/OFQ + NX
*
*
log [N/OFQ], M
in
h
ib
it
io
n
 o
f 
c
o
n
tr
a
c
ti
o
n
(%
)
 
B. C. 
-12 -11 -10 -9 -8 -7 -6
0
10
20
30
40
50
60
70
 *
**
NST
NST+N/OFQ
log [NST], M
in
h
ib
it
io
n
 o
f 
c
o
n
tr
a
c
ti
o
n
(%
)
 
-12 -11 -10 -9 -8 -7 -6
0
10
20
30
40
50
60
70
*
***
NST+N/OFQ+NX
NST+NX
NST
NST+N/OFQ
log [NST], M
in
h
ib
it
io
n
 o
f 
c
o
n
tr
a
c
ti
o
n
(%
)
*
 
Fig. 2. Inhibitory effects of nociceptin (N/OFQ), nocistatin (NST) and naloxone (NX) on pregnant rat 
uterine contractions in vitro.  
A) The contractions were elicited with 25 mM KCl in 22-day-pregnant rat uterine rings. The concentration-
dependent inhibitory effect of N/OFQ (▲) was potentiated by the presence of 10-8 M NX (■). NX alone caused a 
non-significant inhibition of KCl-evoked contractions (data not shown); n=8. B) The contractions were elicited 
with 1 μM prostaglandin F2 alpha. The concentration-dependent inhibitory effect of NST (●) was increased by 
N/OFQ (∆); n=6. C) The contractions were elicited with 25 mM KCl in 22-day-pregnant rat uterine rings. The 
concentration-dependent inhibitory effect of NST (●) was increased by N/OFQ (∆); n=6. The concentration-
dependent inhibitory effect of NST (●) was significantly attenuated by NX (■); n=10. When NST, N/OFQ and 
NX were present, the joint effect of the three drugs (◊) was decreased as compared with the dual effect of NST 
and N/OFQ (∆); n=6. 
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Substance logEC50 (± S.E.M.) Emax (% ± S.E.M.) 
N/OFQ -10.03 ± 0.40  27.55 ± 3.09  
N/OFQ+NX -10.48 ± 0.30 ns 39.27 ± 3.18 * 
Table 3. logEC50 and maximum contraction-inhibitory values of nociceptin (N/OFQ) alone and in the presence 
of naloxone (NX) on KCl-stimulated uterine contractions in the 22-day-pregnant rat in vitro (n=8). *P<0.05, ns: 
nonsignificant; significances are expressed relative to N/OFQ. 
Substance logEC50 (± S.E.M.) Emax (% ± S.E.M.) 
NST (on PGF2α-evoked contraction) -10.92 ± 0.22  25.90 ± 3.16   
NST + N/OFQ -11.07 ± 0.21 ns 38.71 ± 4.26 * 
NST (on KCl-evoked contraction) -8.02 ± 0.18  56.10 ± 4.82  
NST + N/OFQ -7.75 ± 0.27 ns 65.78 ± 9.42 *  
NST + N/OFQ + NX  -8.17 ± 0.27 b 40.33 ± 2.73  a 
Table 4. logEC50 and maximum contraction-inhibitory values of nocistatin (NST) alone and in the presence of 
nociceptin (N/OFQ) on prostaglandin F2 (PGF2α) or KCl-stimulated contractions; and of NST with N/OFQ+NX 
on KCl-stimulated contractions in the 22-day-pregnant rat uterus in vitro (n=8). 
*P<0.05, ns: nonsignificant; significances are expressed relative to NST alone. a: P<0.05, b: nonsignificant; 
significances are expressed relative to NST in the presence of N/OFQ.  
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4.1.4.2. Investigation of the role of BKCa channels in mediating the effects of N/OFQ and 
NST 
Because the central actions of N/OFQ and NX are mediated via the activation of the BKCa 
channels and hyperpolarization of the neurons, the effects of N/OFQ and NX on the uterine 
samples were also tested in the presence of the nonselective K
+
 channel inhibitor TEA (10
-3
 
M) and the BKCa channel-selective inhibitor PAX (5x10
-6 
M) (Fig. 3A, B). In these 
experiments the rhythmic uterine contractions were evoked by oxytocin instead of KCl. TEA 
and PAX themselves did not change the pattern of oxytocin-induced contractions. However, 
the uterus-relaxing effect of N/OFQ on oxytocin-evoked rhythmic contractions was 
significantly attenuated by TEA and PAX. Similarly, when both N/OFQ and NX were 
present, their common contraction-inhibiting effect was significantly decreased by TEA and 
PAX (n=6 for each set of experiments). 
The effects of NST on the spontaneous contractions of the term-pregnant rat uterus were also 
tested in the presence of the selective BKCa channel inhibitor PAX (5x10
-6
 M), (Fig. 3C). In 
the presence of PAX, the maximum contraction-inhibitory effect of NST was decreased 
significantly, while there was no significant difference between the logEC50 values (Table 5). 
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Fig. 3. Effects of potassium channel inhibitors on the pregnant contraction-inhibitory effects of nociceptin 
(N/OFQ) and nocistatin (NST) in vitro. A) The contractions were elicited with 10
-8
 M oxytocin in 22-day-
pregnant uterine rings from the rat. The concentration-dependent relaxing effect of N/OFQ (▲) was decreased 
both by the nonselective K
+
 channel inhibitor tetraethylammonium (TEA; 10
-3
 M; ○) and by the outward 
rectifying K
+
 channel inhibitor paxilline (PAX; 5x10
-6 
M; ). No significant difference was found between the 
effects of the two K
+
 channel blockers (n=6). B) The relaxing effect of N/OFQ was slightly increased by 
naloxone (NX; 10
-8
 M; ■). Their joint effect was decreased both by the nonselective K+ channel inhibitor TEA 
(10
-3
 M; ○) and by the outward rectifying K+ channel inhibitor PAX (5x10-6 M; ). No significant difference was 
found between the effects of the two K
+
 channel blockers (n=6). C) The spontaneous contractions were recorded 
in 22-day-pregnant uterine rings from the rat. The concentration-dependent inhibitory effect of NST (●) was 
decreased by PAX (∆); n= 8. 
Substance logEC50 (± S.E.M.) Emax (% ± S.E.M.) 
N/OFQ (oxytocin) -9.58 ± 0.40  30.89 ± 3.65  
N/OFQ+TEA -9.14 ± 0.34 ns 10.60 ± 1.73 ** 
N/OFQ+PAX -9.60 ± 0.83 ns 15.14 ± 2.73 * 
N/OFQ+NX -9.89 ± 0.34  38.07 ± 3.95  
N/OFQ+NX+TEA -8.99 ± 0.42 c 16.54 ± 2.12 a 
N/OFQ+NX+PAX -9.12 ± 0.90 c 17.75 ± 2.32 b 
NST (spontaneous) -8.29 ± 0.45  33.04 ± 2.83  
NST + PAX -9.47 ± 0.93 d 11.15 ± 3.61 *** 
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Table 5. logEC50 and maximum inhibitory effects of nociceptin (N/OFQ) alone or combined with naloxone 
(NX) in the presence of tetraethylammonium (TEA; 10
-3
 M) or paxilline (PAX; 5x10
-6 
M) on oxytocin-evoked 
uterine contractions; and of nocistatin (NST) in the presence of PAX (5x10
-6 
M) on spontaneous uterine 
contractions in the 22-day-pregnant rat in vitro. *P<0.05, **P<0.01, ns:nonsignificant; significances are 
expressed relative to N/OFQ alone. a: P<0.05, b: P<0.01, c: nonsignificant; significances are expressed relative 
to N/OFQ+NX. ***P<0.001, d: nonsignificant; significances are expressed relative to NST. 
4.1.4.3. Investigation of the contraction-inhibitory effects of NST and NX in a 
hypocalcemic environment  
In the hypocalcemic environment, the concentration—response curves of NST alone and of 
NST in combination with NX were both shifted to the left as compared with the curves in 
standard de Jongh solution. The logEC50 values of NST alone and of NST with NX were 
significantly lower in the hypocalcemic environment than in standard de Jongh solution 
(P<0.05). At the same time, NX did not decrease the inhibitory effect of NST in the 
hypocalcemic environment as it did in the standard buffer. The maximum contraction-
inhibitory effect of NST alone did not differ from that of NST in combination with NX in the 
hypocalcemic buffer (Fig. 4, Table 6). 
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Fig. 4. Effects of nocistatin (NST) and naloxone (NX) on pregnant uterine contractions in a hypocalcemic 
environment in vitro.  
The contractions were elicited with 25 mM KCl in 22-day-pregnant rat uterine rings. The concentration-
dependent inhibitory effect of NST (○) was not altered by NX (□) in the hypocalcemic buffer, whereas it was 
inhibited in the standard Ca
2+
-containing buffer (● NST; ■ NX); n= 6. 
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Substance logEC50 (± S.E.M.) Emax (% ± S.E.M.) 
NST (1 mM Ca
2+
) -8.02± 0.18  56.10 ± 4.82  
NST + NX (1 mM Ca
2+
) -8.01± 0.47 ns 24.78 ± 3.08  a 
NST (0.5 mM Ca
2+
) -10.42± 0.23 b 47.21 ± 4.27  
NST + NX (0.5 mM Ca
2+
) -10.66± 0.24 ns; b 47.82 ± 4.85  ns 
Table 6. logEC50 and maximum contraction-inhibitory effects of nocistatin (NST) alone and in the presence of 
naloxone (NX) on KCl-stimulated uterine contractions in the 22-day-pregnant rat in vitro, either in standard 
Ca
2+
-containing or in hypocalcemic de Jongh solutions (n=6). 
a: P<0.001, ns: nonsignificant. The significances of the joint effect of NST + NX are expressed relative to NST 
alone in the same Ca
2+
-containing de Jongh solution. b: P<0.05; significances are expressed relative to the same 
substance in a different Ca
2+
-containing de Jongh solution.  
4.1.4.4. Investigation of the role of CGRP in mediating the effects of NST 
Since the exact site of action of NST is still unclear, we tested whether it might act by 
modulating neuropeptide release from capsaicin-sensitive sensory nerve endings in the 
pregnant rat uterus. Neuropeptide depletion from the capsaicin-sensitive primary afferents 
was induced with capsaicin (Fig. 5). The maximum contraction-inhibitory effect of NST was 
decreased significantly (P<0.01) after preincubation with capsaicin (1 µM; Table 7). The 
solvent of capsaicin (control) did not change the effect of NST (P>0.05).  
When the neuropeptide depletion was followed by the addition of CGRP (0.1 µM), the 
maximum contraction-inhibitory effect of NST was significantly higher than after incubation 
with capsaicin (P<0.01). The addition of CGRP restored the inhibitory effect of NST as 
compared with the control (P>0.05). 
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Fig. 5. The role of calcitonin gene-related peptide (CGRP) on the contraction-inhibitory effect of 
nocistatin (NST) in vitro. 
The contractions were elicited with 25 mM KCl in 22-day-pregnant rat uterine rings. The concentration-
dependent inhibitory effect of NST (●; control) was reduced significantly after preincubation with capsaicin (□; 
1 µM). Addition of CGRP (0.1 µM) after preincubation with capsaicin caused a significant elevation of the 
concentration—response curve of NST (∆); n= 6. 
Substance logEC50 (± S.E.M.) Max. inhibition at 10
-7 
M 
nocistatin (% ± S.E.M.) 
NST control -9.04 ± 0.43  48.72 ± 7.18  
NST preincubated with capsaicin not converged   6.14 ± 4.79 a 
NST preincubated with capsaicin and CGRP -9.06 ± 0.46  35.05 ± 7.38  a 
Table 7. logEC50 and maximum contraction-inhibitory effects of nocistatin (NST) after preincubation with 
capsaicin (1 µM), with the solvent of capsaicin (control) and with capsaicin (1 µM) and CGRP (0.1 µM) (n=6). 
a: P<0.01. Significances after preincubation with capsaicin are expressed relative to NST alone, and 
significances after preincubation with capsaicin and CGRP are expressed relative to preincubation with capsaicin 
alone. 
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4.1.5. Measurement of PNOC mRNA in the rat uterus 
The myometrial PNOC mRNA levels increased significantly as term was approached. The 
PCR study showed that the levels of PNOC mRNA/β-actin mRNA and PNOC 
mRNA/GAPDH mRNA were lowest on pregnancy day 18. The relative expression of PNOC 
mRNA on day 20 was not different from that on day 18, but it was increased significantly by 
day 22, the day of delivery; P<0.001 (Fig. 6, the endogenous control was β-actin; we 
observed the same results with GAPDH, data not shown).  
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Fig. 6. Levels of expression of PNOC mRNA in the rat uterus on days 18, 20 and 22 of pregnancy 
As term was approached, the PNOC mRNA level increased; there was a significant increase in the level of 
PNOC mRNA in uterus samples obtained from rats on day 22 (i.e. at term) as compared with that on day 20 of 
pregnancy (n=3); ***P<0.001, ns: non-significant. Significances are expressed relative to the previous column. 
The endogenous control is β-actin.  
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4.1.6. Measurement of uterine cAMP accumulation 
In order to investigate the mechanism by which N/OFQ inhibits uterine contractions, the 
effect of N/OFQ on uterine cAMP accumulation was also measured (Fig. 7). The N/OFQ (10
-
8
 M) and NX (10
-8
 M)-stimulated uterine cAMP accumulations were detected in the presence 
of the non-specific phosphodiesterase inhibitor IBMX (10
-3
 M) and the adenylyl cyclase 
activator forskolin (10
-5
 M). N/OFQ alone did not evoke a significant increase (P>0.05) in the 
uterine cAMP accumulation (14.0 ± 0.6 pmol/mg tissue) as compared with the non-treated 
control samples (13.18 ± 0.2 pmol/mg tissue). However, its combination with NX caused a 
significant elevation (P<0.05) in the uterine cAMP level (15.0 ± 0.7 pmol/mg tissue). 
Moreover, if the uterine tissue samples were preincubated with the Gi protein inhibitor PTX 
(500 ng/ml), N/OFQ with NX elevated the uterine cAMP level far higher (P<0.01) than that 
without preincubation (36.5 ± 0.5 pmol/mg tissue), which points to the involvement of Gs-
proteins in the intracellular signalling pathways of N/OFQ and NX in the pregnant rat uterus 
(n=6 for each set of experiments).  
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Fig. 7. Effects of nociceptin (N/OFQ) on the intracellular cAMP levels in the pregnant rat myometrium. 
N/OFQ itself did not increase the cAMP level as compared with the control (black column). The presence of 
naloxone (N/OFQ+NX) increased the N/OFQ-induced intracellular cAMP level, while the addition of pertussis 
toxin (N/OFQ+NX+PTX) resulted in a robust elevation in cAMP level. n=6; *P<0.05, **P<0.01. 
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We also investigated whether cAMP accumulation plays a role in the contraction-inhibitory 
effect of NST (Fig. 8). NST evoked a significant increase (P<0.001) in the uterine cAMP 
level (15.12 ± 0.40 pmol/mg tissue) as compared with the basic activity (12.82 ± 0.17 
pmol/mg tissue). Co-administration of N/OFQ with NST caused a further elevation in the 
cAMP level (17.48 ± 0.29 pmol/mg tissue; P<0.01). However, when NX was co-administered 
with NST, a significant decrease was detected in the cAMP level (13.35 ± 0.52 pmol/mg 
tissue) as compared with the effect of NST alone (P<0.05). 
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Fig. 8. Effects of nocistatin (NST) on intracellular cAMP levels in the pregnant rat uterus. 
NST caused a significant elevation in cAMP level as compared with the control (black column); ***P<0.001. 
The presence of N/OFQ increased (**P<0.01), while NX decreased (*P<0.05) the NST-induced intracellular 
cAMP accumulation; n=6.  
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4.2. Investigations on pregnant human myometrium obtained from full-term pregnancy 
and from preterm birth 
4.2.1. In vitro contractility studies in the full-term pregnant human myometrium 
N/OFQ alone decreased the uterine contractility concentration-dependently. NST (10
-8
 M) 
increased the maximum contraction-inhibitory effect of N/OFQ significantly (P<0.001; Fig. 
9A, Table 8). There was no significant difference between the logEC50 values (data not 
shown). NST alone exerted a contraction-inhibitory effect. However, co-administration of 
N/OFQ (10
-8
 M) with NST did not alter the inhibitory effect of NST (P>0.05; Fig. 9B). There 
was no significant difference between the logEC50 values (data not shown). 
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Fig. 9. Uterus-relaxant effects of nociceptin (N/OFQ) and nocistatin (NST) on the term-pregnant human 
myometrium in vitro. The contractions were elicited with 10
-8
 M oxytocin in uterine rings from full-term human 
pregnancies. A) The concentration-dependent inhibitory effect of N/OFQ (▲) was significantly increased in the 
presence of NST (10
-8
 M; ∆); n=6. B) The concentration-dependent inhibitory effect of NST (●) was not altered 
by N/OFQ (10
-8
 M; ○); n=4. 
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4.2.2. In vitro contractility studies in the pregnant human myometrium from 
preterm births 
N/OFQ alone decreased the uterine contractility concentration-dependently. NST (10
-8
 M) 
increased the maximum contraction-inhibitory effect of N/OFQ significantly (P<0.001; Fig. 
10A, Table 8). There was no significant difference between the logEC50 values (data not 
shown). NST alone demonstrated a contraction-inhibitory effect, which was not altered by 
N/OFQ (P>0.05; Fig. 10B). There was no significant difference between the logEC50 values 
(data not shown). 
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Fig. 10. Uterus-relaxant effects of nociceptin (N/OFQ) and nocistatin (NST) on the preterm-pregnant 
human myometrium in vitro. The contractions were elicited with 10
-8
 M oxytocin in uterine rings from preterm 
human pregnancies. A) The concentration-dependent inhibitory effect of N/OFQ (▲) was significantly increased 
in the presence of NST (10
-8
 M; ∆); n=4. B) Co-administration of N/OFQ (10-8 M) with NST (○), however, did 
not significantly alter the inhibitory effect of NST (●); n=5. 
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Table 8. Maximum contraction-inhibitory values of nociceptin (N/OFQ) alone and in the presence of nocistatin 
(NST); and of NST alone and in the presence of N/OFQ on oxytocin-stimulated uterine contractions on the term- 
and preterm-pregnant human myometrium in vitro. ***P<0.001; significances are expressed relative to N/OFQ. 
ns: non-significant; significances are expressed relative to NST. 
4.2.3. Measurement of PNOC mRNA in the human uterus 
The myometrial PNOC mRNA levels were significantly higher in preterm uterine samples 
(RQ=35.40 ± 3.31) as compared with samples from full-term pregnancy (RQ=0.81 ± 0.12); 
P<0.001 (Fig. 11). 
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Fig. 11. Levels of expression of PNOC mRNA in human uterus samples obtained from preterm birth and 
full-term birth. By term pregnancy, the PNOC mRNA level was decreased; there was a significant decline in 
the level of PNOC in full-term uterine samples as compared with preterm samples; ***P<0.001. 
 Emax (% ± S.E.M.)  Emax (% ± S.E.M.) 
Term-pregnant uterus   Preterm-pregnant uterus   
N/OFQ 29.07 ± 1.61   N/OFQ 27.51 ± 4.31  
N/OFQ + NST 43.79 ± 3.61  *** N/OFQ + NST 56.29 ± 4.94 *** 
NST  42.01 ± 9.48  NST 35.55 ± 6.58  
NST + N/OFQ 38.24 ± 7.05 ns  NST + N/OFQ 37.92 ± 7.40 ns 
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5. Discussion  
PNOC mRNA is expressed predominantly in the central nervous system (the brain and spinal 
cord). A previous study also confirmed its presence in human peripheral blood mononuclear 
cells (Williams et al., 2008), and it has been detected in the rat ovary (Mollereau et al., 1996 
and Leo et al., 2001). In the human brain, Foradori et al. (Foradori et al., 2007) found that 
gonadotropin releasing hormone (GNRH) immunoreactive nerve cells co-localize N/OFQ in a 
high percentage. These findings strongly indicate that the actions of GNRH are modulated in 
part by N/OFQ, this mechanism controlling the reproductive functions by regulating release 
of the gonadotropic hormones FSH and LH from the pituitary. However, the expressions of 
PNOC mRNA as well as the presence and effects of N/OFQ and NST have not been 
investigated to date in the female rat and human uterus.  
5.1. Myometrial expression of PNOC mRNA, NOP, N/OFQ and NST  
We found that the common precursor for N/OFQ and NST, the PNOC mRNA, is expressed 
locally in the pregnant rat and human uterus, indicating that N/OFQ and NST are synthesized 
locally. The expression of PNOC mRNA was high on the last day of pregnancy in the rat as 
compared with earlier days. The RIA results confirmed the presence of both N/OFQ and NST 
in the nonpregnant and the pregnant rat uterus. Furthermore, we found that NST in the 
pregnant rat uterus at term is about 10 times more abundant than N/OFQ, so it seems that 
PNOC mRNA is translated mainly to NST, rather than N/OFQ. As regards the higher 
contractility during delivery, the elevation of N/OFQ and NST levels in the myometrium at 
term appears rather contradictory, since they have uterus relaxing effect. Nevertheless, they 
have regulatory role in pain signalling, which may explain their functional importance during 
labour. In the human samples PNOC shows an elevated level in preterm pregnancies, which is 
in correlation with the uterine quiescence during pregnancy, although it is contrary to the 
results obtained from the rat. Much more NST and N/OFQ can be translated from PNOC in 
preterm pregnancy than in the term pregnancy. The PNOC level drops by the end of 
pregnancy, when uterine contractility becomes stronger.  
We also detected specific binding sites for NOP both in the nonpregnant and term-pregnant 
rat uterus, their concentration being similar to that in most brain regions (Clarke et al., 2003). 
This may suggest that pro-nociceptive peptides are likely to be involved in local mechanisms 
regulating the uterine functions at term.  
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5.2. In vitro contractility studies 
The idea that endogenous pro-nociceptive substances might have a modulating effect on the 
uterine smooth muscle contractility stems from the ancient experience that labour contractions 
are extremely painful. Thus, labour pain and powerful contractions are usually related.  
As regards its effects on the uterus, N/OFQ was found to inhibit both KCl- and oxytocin-
evoked rhythmic contractions. In order to exclude the possible involvement of classical opioid 
receptors in the mediation of this effect, NX was co-administered with N/OFQ onto the 
isolated uterine tissue samples. Our results revealed that NX significantly increased the 
uterus-relaxing effect of N/OFQ, suggesting that NX has a relaxing effect on its own. The 
effect of NX alone on the uterus appeared to be nonsignificant. The potentiating effect of NX 
may seem unexpected, but a publication reported an elevated uterine tone in humans after 
intrathecal administration of opioids during labour (Abrão et al., 2009), which suggests that 
endogenous opioids might have a contraction-enhancing effect on the uterus that can be 
attenuated by NX.  
Although NST possesses a contraction-inhibitory effect on KCl- and PGF2-evoked 
contractions, its action was weak against PGF2. N/OFQ was able to potentiate the inhibitory 
effect of NST in both cases. NST does not counteract the effects of N/OFQ on the 
myometrium contractility, as was presumed in previous studies relating to their actions in the 
central nervous system. However, NST was ineffective on oxytocin-induced contractions. 
This phenomenon will be discussed later (see Section 5.6.) with regard to a detailed 
mechanism of the action of NST on the pregnant rat myometrium. 
NX inhibits the contraction-inhibitory effect of NST against KCl-induced contractions. 
NST does not bind to any of the classical opioid receptors, or to the NOP receptor (Johnson 
and Connor, 2007 and Fantin et al., 2007), thus this inhibition is not likely to be mediated by 
opioid receptors. It was demonstrated that NX induces an increase in inward Ca
2+
 currents 
(Kai et al., 2002). These findings led us to investigate whether the inhibitory effect of NX on 
NST-induced uterus relaxation is mediated by the opening of inward rectifying Ca
2+
 channels. 
To test our hypothesis, we used a hypocalcemic environment, where NX did not inhibit the 
effect of NST. We presume that, in a low extracellular Ca
2+ 
concentration, NX is probably 
unable to promote a Ca
2+
 influx, and hence it can not overcome the relaxation induced by 
NST. The leftward shift in the concentration—response curves are likely to be due to the 
weaker tissue contractility, caused by the lower Ca
2+
 content. When N/OFQ was present, NX 
was able to decrease the common contraction-inhibitory effect of NST and N/OFQ. However, 
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although NX increases the effect of N/OFQ, the effect seen here is probably the consequence 
of the more pronounced inhibitory effect of NST as compared with that of N/OFQ.  
5.3. Investigation of G protein-activating potency  
After the description of the contraction-inhibitory effect of N/OFQ and NST in the in 
vitro contractility studies, our further aim was to investigate some of the potential signalling 
pathways.  
The high homology between the NOP receptor and the three opioid receptor subtypes raised 
the question of whether the NOP receptor is a Gi coupled receptor that regulates adenylyl 
cyclase activity, K
+
 channels and voltage-gated Ca
2+
 channels. The cellular actions of N/OFQ 
were found to be similar to those of opioids, i.e. inhibition of the formation of cAMP, closure 
of voltage-sensitive Ca
2+
 channels, and enhancement of outward K
+
 conductance (Hawes et 
al., 2000). Hence, we also tested the G protein-activating effect of N/OFQ on the term-
pregnant rat uterus, and found a significant elevation of [
35S]GTPγS binding through the NOP 
receptors. Thus, G proteins at least in part, mediate the actions of N/OFQ on the uterus. 
Furthermore, the presence of NX decreased the maximum [
35S]GTPγS binding and at the 
same time increased the uterus-relaxing effect of N/OFQ. A possible explanation for this 
phenomenon might be that NX interferes with the Gi protein-activating potency of N/OFQ. In 
the presence of NX and PTX, which uncouples the receptor from the Gi protein and prevents 
the inhibition of adenylyl cyclase activity, we detected a dramatic fall in N/OFQ-induced G 
protein production. This inhibition of the Gi proteins resulted in activation below the basal 
level. The phenomenon that individual receptors are able to activate multiple pathways by 
switching between different G proteins is well established (Lefkowitz et al., 2002; Knollman 
et al., 2008). The coupling of beta-adrenergic receptors to Gs proteins leads to the activation 
of adenylate cyclase and the consequent phosphorylation of protein kinase A (PRKA), which 
phosphorylates the receptor and diminishes its coupling to Gs, but increases the coupling to 
Gi. We presume that NX interferes with the intracellular pathways activated by N/OFQ and 
promotes its coupling to Gs. This mechanism results in an elevation of the myometrial cAMP 
level and uterus relaxation. N/OFQ can effectively activate protein kinase C via NOP 
receptor, through a pertussis toxin (PTX)-sensitive G-protein activation (Gi/0). Besides, it has 
been shown, that phospholipase C (PLC) inhibitors block this pathway, which means, that 
Ca
2+
 concentration is increased, and thus phospholipase C activation are involved in the 
signalling mechanism (Lou et al., 1997). 
  39 
5.4. Measurement of cAMP accumulation 
In order to investigate further the mechanism by which N/OFQ and NST inhibit 
uterine contractions, the effects of N/OFQ and NST on uterine cAMP accumulation were also 
measured. Co-administration of NX with N/OFQ increased the uterine cAMP level. To test 
the participation of Gs proteins in the actions of N/OFQ, the changes in cAMP level in the 
uterus were assessed in the presence of PTX. In this experiment, the cAMP level rose 
markedly, which suggests that NOP receptors are probably coupled to both Gi and Gs proteins 
in the late-pregnant rat uterus, and Gs stimulation is responsible for the elevated cAMP level. 
We also presume that N/OFQ and NX compete for intracellular Gi protein activation. We 
detected elevation of cAMP levels in the presence of NST. In the presence of N/OFQ with 
NST, a further cAMP level elevation was found, which can be explained by the mutual 
cAMP-accumulating effects of N/OFQ and NST-induced CGRP liberation (Klukovits et al., 
2010 and Dong et al., 2005). In correlation with the in vitro contractility studies, NX 
decreased the cAMP levels elevated by NST, which suggests that NX interferes with NST at 
the level of G-protein activation, too.  
5.5. Investigation of the role of K
+
 channels in mediating the effects of N/OFQ and NST 
However, the changes in local cAMP levels do not seem to be the only intracellular pathway 
regulated by N/OFQ and NST. N/OFQ has been reported to enhance an outward K
+
 
conductance, which reduces neuronal excitability and transmitter release in the brain (Hawes 
et al., 2000). In the uterus, BKCa channels are abundant and play an important role in limiting 
depolarization, thereby relaxing the uterine smooth muscle. Moreover, these BKCa channels 
are activated by a cAMP-dependent phosphorylation pathway (Chanrachakul et al., 2004). 
We set out to investigate the role of K
+
 currents in the intracellular signalling of N/OFQ and 
NST. We found that blockade of the K
+
 channels with TEA or PAX diminishes the uterus-
relaxing effect of N/OFQ, applied either alone or in combination with NX, which suggests 
that this effect of N/OFQ on the pregnant rat uterus is mediated by the activation of K
+
 
channels. There was no difference between the N/OFQ-inhibiting effects of the non-selective 
K
+
 channel blocker TEA and the BKCa-selective blocker PAX. This result suggests that BKCa 
channels may have a crucial role in the uterus-relaxing effect of N/OFQ. In the presence of 
TEA or PAX, N/OFQ alone or in combination with NX still produced a limited uterus-
relaxing effect, which is suspected to be mediated by the elevated cAMP level. PAX inhibited 
the contraction-inhibitory effect of NST, as evidence that the Ca
2+
-dependent K
+
 channels 
play a role in the intracellular signalling of NST as well. 
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5.6. Role of sensory neuropeptide CGRP 
It is known, that inflammatory mediators play a role in the initiation of labour, yet some of 
them (e.g. CGRP) exhibit utero-relaxant activity among their various effects. Opioid-like 
nociceptive peptides have been reported to release neurotransmitters such as CGRP or 
substance P (SP) from capsaicin-sensitive primary sensory neurons (Peiser et al., 2000 and 
Helyes et al., 1997). These neuropeptides are synthesized in the dorsal root ganglia (DRG) 
cells, stored in vesicles and released by exocytosis (Lundberg et al., 1996) in response to 
electrical (Markowitz et al., 1987 and Buzzi et al., 1991) or chemical stimulation (Kilo et al., 
1997). CGRP has been reported to inhibit smooth muscle contractility in a variety of tissues, 
including the pregnant rat uterus (Pennefather et al., 1990). Other studies have reported that 
the binding of 
125
I-CGRP to rat uterine membranes was increased during pregnancy and 
decreased during parturition (Yallampalli et al., 1999).  
The potential involvement of CGRP in the actions of NST on the pregnant rat uterus was 
therefore also tested. While capsaicin causes the depletion of CGRP from sensory nerve 
terminals (Holzer, 1991), other studies have furnished evidence of a CGRP reload into the 
sensory nerve terminals after depletion by capsaicin (Sams-Nielsen et al., 2001). We 
investigated the effect of NST either on capsaicin-induced CGRP-depleted uterus samples or 
on CGRP-reloaded uterus samples. Capsaicin blocked the contraction-inhibitory effect of 
NST, which was restored after the tissue samples were incubated with CGRP. Consequently, 
we assume that CGRP is an important factor in the contraction-inhibitory effect of NST. To 
support the hypothesis of the cross-talk between NST and CGRP, a special population of 
opioid receptors in DRG neurons was reported, where low doses of opioids can provoke 
hyperalgesia, due to the activation of excitatory opioid receptors on the afferent nerve 
terminals (Crain and Shen, 2000). This phenomenon involves an increased release of 
excitatory neuropeptides, including CGRP and SP, in the spinal cord (Xu et al., 2003, 
Wiesenfeld-Hallin et al., 1991 and Crain and Shen, 1990]. We assume that NST, similarly to 
opioid peptides and N/OFQ, may promote the release of neuropeptides from sensory nerves 
(Moran et al., 2000). This mechanism may explain the ineffectiveness of NST against 
oxytocin-induced contraction; it was reported that the CGRP-agonist adrenomedullin also 
failed to block oxytocin-evoked contractions, whereas it was effective against spontaneous 
and bradykinin-induced contractions (Yanagita et al., 2000). 
In the human tissues NST administration must precede the administration of N/OFQ with the 
aim of enhancing the common uterus-relaxant effect. We assume that the CGRP-liberating 
effect of NST results in a weaker relaxation as compared with the potassium channel opening 
  41 
effect of N/OFQ; repeated and increasing administrations of N/OFQ following NST can 
therefore further increase the uterus relaxation through the potassium channels. On the other 
hand, if N/OFQ is administered first, the CGRP liberating effect of NST cannot exceed the 
relaxation caused by a single dose of N/OFQ through potassium channel opening, therefore 
the relaxing effect of NST cannot be potentiated by N/OFQ significantly. The more prominent 
potentiating effect of NST in N/OFQ-stimulated uterus relaxation in preterm birth as 
compared with term pregnancy correlates with the finding that PNOC is more abundant in 
preterm birth.  
As NOP is expressed in a high proportion of substance P (SP)/CGRP-positive neurons, and as 
a major subpopulation of N/OFQ neurons is located in juxtaposition to SP/CGRP-positive 
neurons, it is proposed that N/OFQ released locally in the dorsal root ganglia may (in a 
paracrine manner) modulate SP/CGRP-containing neurons expressing NOP. Thus, N/OFQ 
modulates both central and peripheral SP- or CGRP-mediated neurotransmission (Mika et al., 
2003). 
6. Conclusions 
These results provide evidence that both N/OFQ and NST generated locally in the uterus have 
contraction-inhibitory effect in the pregnant rat and human uterus, and when they are 
administered together, they can potentiate each others effect, this mechanism being mediated 
mainly by BKCa channels and consequent hyperpolarization. NST additionally acts by release 
of the sensory neuropeptide CGRP. NX shows an additive relaxant effect with those of 
N/OFQ, on the other hand it overcomes the relaxation caused by NST by activating inward 
rectifying Ca
2+
 channels and by decreasing the cAMP-accumulating effect of NST. We have 
provided evidence that the NOP receptors are coupled to multiple G proteins. We assume that, 
N/OFQ or NOP-related (preferably non-peptide) agonists as well as NST derivatives might be 
considered as prospective candidates for tocolytic therapy. The findings of this in vitro study 
need to be evaluated under in vivo conditions, and further experiments on human tissue are 
necessary in order to allow conclusions on the relevance of the present findings as concerns 
human disease. 
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